2024
70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)
HEROLD K, DAYAN C, CHATENOUD L, GITELMAN S, SUMNIK Z, SIMMONS K, SZYPOWSKA A, KNECHT L, NIEMOELLER E, TIAN W, RAMOS E. 70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D). Diabetes 2024, 73 DOI: 10.2337/db24-70-or.Peer-Reviewed Original ResearchIntent-to-treatInsulin doseFunction preservationPer-protocolIntent-to-treat populationß-cell functionAnti-CD3 mAbReduced insulin doseLower insulin doseSustained glycemic controlPP populationTeplizumabMetabolic outcomesPBO groupHbA1c levelsPP analysisGlycemic controlTreatment complianceDoseDelayed onsetRandomized participantsIncorrect treatmentInsulinWeeksTreatment
2009
The IRS2 Gly1057Asp Variant Is Associated With Human Longevity
Barbieri M, Rizzo M, Papa M, Boccardi V, Esposito A, White M, Paolisso G. The IRS2 Gly1057Asp Variant Is Associated With Human Longevity. The Journals Of Gerontology Series A 2009, 65A: 282-286. PMID: 19887537, DOI: 10.1093/gerona/glp154.Peer-Reviewed Original ResearchConceptsInsulin receptor substrate 2Gene polymorphismsYears of ageIGF-1 signalingß-cell functionInsulin-like growth factor-1 signalingIrs2 branchInsulin resistanceInsulin sensitivityMetabolic covariatesGly1057Asp variantIRS2 geneExtreme old ageLarge population groupsInternal medicineC participantsOlder ageHuman longevityCommon polymorphismsIGF signalingInsulinFurther studiesPopulation groupsAgeWhole population
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply